These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9914870)

  • 21. Newer approaches to the management of multiple myeloma.
    Kyle RA
    Cancer; 1993 Dec; 72(11 Suppl):3489-94. PubMed ID: 8242581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition and multiple myeloma.
    Kanagasabaphy P; Morgan GJ; Davies FE
    Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of topoisomerase I inhibitors in multiple myeloma.
    Kraut EH; Ju R; Muller M
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
    Dunkley S; Gibson J; Iland H; Li C; Joshua D
    Leuk Lymphoma; 1999 Nov; 35(5-6):623-6. PubMed ID: 10609802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance in multiple myeloma: approaches to circumvention.
    Dalton WS; Jove R
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
    Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
    Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple myeloma: biology of the disease.
    Mahindra A; Hideshima T; Anderson KC
    Blood Rev; 2010 Nov; 24 Suppl 1():S5-11. PubMed ID: 21126636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic factors in multiple myeloma].
    Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede P; Palumbo A; Pileri A
    Haematologica; 1989 Oct; 74(5 Suppl):347-57. PubMed ID: 2512219
    [No Abstract]   [Full Text] [Related]  

  • 33. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
    Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
    Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The plasma cell myeloma--molecular pathogenesis and target therapies].
    Hess U
    Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anti-myeloma agents and angiogenesis.
    Anargyrou K; Dimopoulos MA; Sezer O; Terpos E
    Leuk Lymphoma; 2008 Apr; 49(4):677-89. PubMed ID: 18398734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
    Pilarski LM; Mant MJ; Belch AR
    Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
    Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
    Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.